Trending news

Kathy Williams, a partner in Nutter’s Intellectual Property Department and chair of the firm’s Life Sciences group, addressed the Massachusetts biotech industry in Law360. In the article, “How Attys Are Riding The Mass. Biotech 'Roller Coaster',” Kathy said, “I am seeing a lot of early-stage companies that are seeking money, and what I hear from investors is they are very selective and picky because they are uncertain of the economy and where this is going, especially government funding in healthcare. There's a lot of uncertainty that's driving investors to be very cautious. But I must say, when they do see a company they consider valuable to invest in, they put a lot of money into it.”